- ►pubget.com [PDF] S Ennis, C Jomary, R Mullins, A Cree, X Chen, … - The Lancet, 2008 - Elsevier Age-related macular degeneration is the most prevalent form of visual impairment
and blindness in developed countries. Genetic studies have made advancements in
establishing the molecular cause of this disease, identifying mutations in ... Cited by 21 - Related articles - All 21 versions
MS Ip, IU Scott, GC Brown, MM Brown, AC Ho … - Ophthalmology, 2008 - Elsevier Literature searches were conducted in May and October 2007 in PubMed with no
date restrictions, limited to articles published in English, and in the Cochrane
Central Register of Controlled Trials without a language limitation and ... Cited by 13 - Related articles - All 5 versions
H Dadgostar, N Waheed - Eye, 2008 - nature.com Age-related macular degeneration (AMD) is the leading cause of blindness among
the ageing population. The introduction of molecular inhibitors of vascular
endothelial growth factor (VEGF), such as pegaptanib, ranibizumab, and ... Cited by 9 - Related articles - All 3 versions
- ►prsjournal.com LJ Hernandez-Pastor, A Ortega, A Garcia- … - American Journal of Health-System Pharmacy, 2008 - pt.wkhealth.com LUIS JAVIER HERNANDEZ-PASTOR, PHARM D., is Resident, Pharmacy Department,
University Clinic; ANA ORTEGA, PHARM.D., PH.D., is Consultant Pharmacist,
Clinica Universitaria, and Assistant Professor, Faculty of Pharmacy; ... Cited by 5 - Related articles - All 8 versions
J Levy, M Shneck, S Rosen, I Klemperer, D … - International Ophthalmology, 2009 - Springer Abstract Objective To report the visual and anatomic outcome of intravitreal
bevacizumab (Avastin) injec- tions in the treatment of subfoveal neovascular
age-related macular degeneration (AMD). Methods Interventional, ... Cited by 5 - Related articles - All 2 versions
C Costagliola, U Cipollone, M Rinaldi, M … - British Journal of Clinical Pharmacology, 2008 - prsjournal.com AIMS: Neovascular glaucoma (NVG) represents one of the most severe forms of
secondary glaucoma, caused by a number of ocular and systemic conditions, which
share the common element of retinal ischaemia/hypoxia that initiates the ... Cited by 5 - Related articles - Cached - All 6 versions
SF Hurley, JP Matthews, RH Guymer - Cost Effectiveness and Resource Allocation, 2008 - resource-allocation.com We assessed the cost-effectiveness of ranibizumab compared with no ranibizumab
over 10 years, using randomized trial efficacy data for the first 2 years,
post-trial efficacy assumptions, and ranibizumab acquisition costs ranging ... Cited by 3 - Related articles - Cached - All 11 versions
MR Barakat, PK Kaiser - Expert Opinion on Investigational Drugs, 2009 - Informa Pharma Science Age-related macular degeneration (AMD) is the leading cause of blindness in the
Western world for those patients aged 50 years or older. Neovascular AMD, a
subtype characterized by the growth of new, pathologic blood vessels, ... Cited by 3 - Related articles - All 6 versions
MS Spitzer, F Ziemssen, KU Bartz-Schmidt, F …, 2008 - pubmedcentral.nih.gov Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms
of VEGF-A, significantly slows down loss of vision and causes significant visual
improvement in many patients with choroidal neovascularization (CNV) due to ... Cited by 2 - Related articles - All 6 versions
DB Rein, JS Wittenborn, X Zhang, AA … - Archives of Ophthalmology, 2009 - archopht.highwire.org Methods We simulated cases of early AMD, choroidal neovascularization (CNV),
geographic atrophy (GA), and AMD-attributable visual impairment and blindness
with 5 universal treatment scenarios: (1) no treatment; (2) focal laser and ... Cited by 2 - Related articles - All 2 versions
